This study involving 93 Egyptian female patients with Frontal Fibrosing Alopecia (FFA) and 157 healthy controls found that FFA patients had significantly lower serum levels of Peroxisome Proliferator Activated Receptors Gamma (PPARγ) and a higher prevalence of the PPARG (Pro12Ala) gene polymorphism. These genetic variations were linked to reduced PPARγ levels and increased FFA severity, suggesting that PPARγ could be a crucial biomarker for FFA. Although the study indicates the potential of PPARγ agonists in treating FFA, it could not evaluate their therapeutic efficacy due to patient compliance issues.
80 citations,
April 2018 in “Trends in Molecular Medicine” Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.
2 citations,
April 2017 in “Actas Dermo-Sifiliográficas” Best treatment for Frontal Fibrosing Alopecia is 5-alpha-reductase inhibitors and intralesional corticosteroids.
38 citations,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
38 citations,
January 2017 in “PPAR Research” PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
24 citations,
November 2019 in “Experimental Dermatology” PPAR-γ is important for healthy hair and its problems, and more research on PPAR-γ treatments is needed.
May 2023 in “Journal of Endocrinology and Reproduction” Blocking cholesterol production may help control hair loss in Primary Cicatricial Alopecia by affecting key regulators.
8 citations,
July 2020 in “Clinical, cosmetic and investigational dermatology” Excessive sun protection might cause frontal fibrosing alopecia by disrupting skin immune balance.